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S U M M A R Y
Objectives: To investigate the relationship between human immunodeﬁciency virus (HIV)-positive and
HIV-negative patients engaging in promiscuous behaviors and anal human papillomavirus (HPV)
infection diagnosed by polymerase chain reaction (PCR) and cytology.
Methods: Fifty-six HIV-positive patients and 49 HIV-negative patients who engaged in sexually
promiscuous behavior were enrolled in the study. We performed cytological exams using the Pap smear
and PCR for HPV-DNA detection, with identiﬁcation of oncogenic strains. The 2001 Bethesda System
terminology was used for the cytological exams. We also evaluated the immunologic status of the HIV-
infected patients.
Results: PCR positivity for HPV-DNAwas higher in the group of HIV-positive patients than in the group of
HIV-negative patients with a statistically signiﬁcant difference. In contrast we did not ﬁnd any
statistically signiﬁcant difference by cytological exam. Oncogenic strains were equally distributed in the
two groups.
Conclusions: Our results indicate the importance of the cytological exam for anal HPV screening in the
population at high risk of sexually transmitted disease and that HPV-DNA PCR can be used only as
adjunct test.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Consistent with the high prevalence of anogenital human
papillomavirus (HPV) infection, new data show that the incidence
of anal cancer is increasing, even with the introduction of
combination antiretroviral therapy (cART) in the HIV-positive
population.1 As for cervical carcinoma, there is a cause and effect
relationship between anal cancer and HPV infection, especially
with the high-risk types such as HPV16. Anal cancer is potentially
preventable using screening methods similar to those used to
prevent cervical cancer in women.2
To date approximately 100 different genotypes of the virus
have been identiﬁed and 40 of these have a special anal tropism.
The genotypes causing anal lesions have been classiﬁed into
‘low-risk’ and ‘high-risk’ categories.3,4 Low-risk HPV genotypes
(6, 11, 40, 42, 43, 44, 54, 61, 70, 72, and 81) can be the cause of* Corresponding author. Tel.: +39 06 49970313; fax: +39 06 499702625.
E-mail address: ilaria.d@libero.it (I. D’Angeli).
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high-risk genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58,
59, 66, 68, 73, 82) can be the cause of ‘dysplastic’ and ‘malignant’
lesions.5
The HPV genome includes the proteins E1 and E2, which are
involved in viral DNA replication and the regulation of viral gene
expression; E4 is implicated in virus assembly and E5, E6 and E7
are responsible for immortalization and transformation of infected
epithelial cells. Viral DNA integration leads to the over-expression
of the two viral oncoproteins E6 and E7, which form complexes
with the p53 and p105Rb tumor suppressor gene products,
respectively, inhibiting their function.6,7
Similar to cervical counterpart lesions, anal HPV-related lesions
frequently harbor HPV types 6, 11, 16 and 18.8,9
There are conditions that increase the risk of anal lesions:
receptive anal intercourse,10 a history of sexually transmitted
disease,11 number of sexual partners,12 HIV status,13,14 lower CD4
counts,14 and immunosuppression after solid organ transplanta-
tion.15 Anal HPV is transmitted by sexual contact and is common in
men who have sex with men (MSM).16ses. Published by Elsevier Ltd. All rights reserved.
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of the virus. In fact in immune-competent subjects, skin warts
often regress spontaneously, whereas in immune-compromised
patients, such as HIV-infected patients and those who have
undergone transplantation, a higher incidence and persistence of
skin and mucosa infections induced by HPV are found.17,18
To date, there are no guidelines for the screening of anal HPV
infection in the at-risk population, or for treatment.19 From a
review of the literature we only found information for the
screening of cervical cancer, and only recently have some authors
reported the importance of the use of HPV-DNA testing as an
adjunct to cytology in primary screening for women aged 30 years
or older on the basis of the results from cohort studies.20
The aim of this study was to describe the characteristics of the
cytological exam vs. HPV-DNA by polymerase chain reaction (PCR)
for the diagnosis of HPV infection in the anal mucosa in both HIV-
positive and HIV-negative patients who engage in promiscuous
sexual behaviors. Moreover, we sought to evaluate the correlation
between the grade of immunodeﬁciency and the presence of anal
HPV. Finally, we studied the characteristics of those patients from
whom oncogenic strains were isolated.
2. Materials and methods
This study forms part of an ongoing prospective cohort study of
HIV-positive and HIV-negative patients enrolled at the Depart-
ment of Coloproctology and Infectious Diseases of ‘‘Sapienza’’
University Rome, Italy. Enrollment was initially conducted
between May 2004 and April 2008 and included 105 patients:
56 HIV-positive and 49 HIV-negative.
Participants answered an interviewer-administered question-
naire and underwent a proctological examination and brushing of
the anal canal with an endobrush (Biogyn, Mirandola, Italy) for the
detection of HPV-DNA by PCR and anal cytology.
All patients were at high risk of sexually transmitted HPV
infection as a result of promiscuous behavior. Six patients had
small benign anal canal condylomas. Subjects with malignant anal
and peri-anal neoplastic lesions and those who had undergone
previous anal surgery or transplantation were excluded. Patient
demographic, immunological, and virological characteristics are
shown in Table 1.
2.1. Laboratory methods
Specimens for Papanicolaou testing (Pap smear) were collected
using an anal brush. The endobrush was inserted into the anal
canal up to the dentate line (1.5–2.0 cm from the anal margin) andTable 1
Patient demographic, immunological, and virological characteristics
HIV-positive
(56 patients)
HIV-negative
(49 patients)
Age, years, median (range) 42.5 (21–64) 46 (28–68)
Gender, n 50 M; 6 F 40 M; 9 F
Ethnic group, n Caucasian: 56 Caucasian: 49
Risk factors, n
MSM 39 28
Bisexual 11 12
Promiscuous behavior 6 9
2 sex partners in the
past 6 months
27% 22%
CD4 T cell count,
cells/mm3, mean  SD
55044 750  181
HIV-RNA <50 copies/ml
cART 56
Benign condylomas 3 3
HIV, human immunodeﬁciency virus; M, male; F, female; MSM, men who have sex
with men; SD, standard deviation; cART, combination antiretroviral therapy.scraped along the anal walls by rotation three times clockwise and
three times anticlockwise.
All anal cytological analyses were carried out and interpreted at
the Department of Experimental Medicine and Pathology,
‘‘Sapienza’’ University, Rome using the 2001 Bethesda System
criteria for cytological diagnosis by a cytologist with experience in
the ﬁeld of cervical Pap smears.21
For HPV-DNA detection, anal brushings collected in 1 ml
phosphate-buffered saline (PBS), were centrifuged at low speed;
the cell pellets then underwent DNA extraction using a QIAamp
blood kit (Qiagen, Hilden, Germany). To assess the quality of the
target DNA, human leukocyte antigen-speciﬁc primers were used
in a PCR analysis.22 A 450-bp fragment from the L1 region of HPV-
DNA was ampliﬁed using the consensus primers MY09/11.23 To
increase the sensitivity, with the detection of a broader range of
HPV genotypes, a second PCR assay was performed on sample
DNA; the complete E6 gene and part of the E7 gene were ampliﬁed
using four pairs of degenerate consensus primers able to detect 36
HPV types.24 PCR products corresponding to proper fragments
were puriﬁed, and sequencing of the two genomic regions was
performed using an automatic DNA sequencer (model 370A;
Applied Biosystems, Foster City, CA, USA). Sequence homology was
determined as previously described.22 A sample was considered to
be infected with a genotype if at least one PCR and a related
sequence gave a positive result. If both L1 and E6/7 gave weak
positive signals, a sample was considered positive for HPV and not
typed; if only one weak PCR signal was obtained, a second
specimen was tested. If the L1 and E6/7 sequence gave discordant
results, the patient was considered to be infected with two
different HPV genotypes.25 The oncogenic HPV strains in our study
were: 31, 33, 35, 51, 53, 55, 58, 66, 16, and 18. Only two cases of Pap
smear and one case of HPV-DNA by PCR were excluded from the
statistical analysis for the presence of artifacts and fecal
contamination, respectively.
2.2. Statistical methods
Values are given as mean  standard error of the mean (SEM).
Differences between mean values were evaluated for statistical
signiﬁcance using the Chi-square test and Student’s t-test. Stata
statistical software version 11 (Stata Corp., College station, TX, USA)
was used for the analyses.
3. Results
Table 1 shows the characteristics of the study participants at the
time of their study visit.
Of the 56 HIV-positive patients, 38 (67.9%) showed positive
results by HPV-DNA PCR; in the group of 49 HIV-negative patients,
the PCRwas positive in 20 (40.8%) (p< 0.005). Oncogenic genotypes
werepresent in17of the38HIV-positive/HPV-DNA-positive (44.7%)
patients and in six of the 20 HIV-negative/HPV-DNA-positive
patients (30%) (Table 2). The incidence of HPV16 and HPV18 was
10.3% in the 58 HPV-positive patients (of these HPV-positive
patients 8.6% were HIV-positive and 1.7% were HIV-negative).
The cytological exam was positive for HPV infection in 38
(67.9%) HIV-positive patients and in 28 (57.1%) HIV-negative
patients (p = 0.6). Squamous intraepithelial anal lesions (SIL) were
discovered in 12 patients; low-grade squamous intraepithelial anal
lesions (LSIL) were found in 10 patients and high-grade squamous
intraepithelial anal lesions (HSIL) in two patients. SILwere found in
ﬁve HIV-positive patients and seven HIV-negative patients. In four
of these cases (two HIV-positive and two HIV-negative) the PCR
was negative. In the group of HIV-positive/HPV-DNA-positive
patients with SIL (three cases with LSIL) we found genotypes 6, 53
and 70. Genotype 6 was found in all subjects in the group of
Table 2
PCR results and HPV oncogenic and non-oncogenic genotypes
HIV-positive
(number of
patients)
HIV-negative
(number of
patients)
HIV-positive
(%)
HIV-negative
(%)
PCR-negative 18 29 32.1 59.2
PCR-positive 38 20 67.9 40.8
Oncogenic
genotypes
17 6 / /
Non-oncogenic
genotypes
21 14 / /
PCR, polymerase chain reaction; HPV, human papillomavirus; HIV, human
immunodeﬁciency virus.
Table 3
HPV-DNA results and HIV antibody status in patients with Pap smears positive for
LSIL and HSIL
Patient Cytology HPV-DNA HIV antibodies
1 LSIL 6 Positive
2 LSIL 70 Positive
3 LSIL 53 Positive
4 LSIL Negative Positive
5 LSIL Negative Positive
6 LSIL 6 Negative
7 LSIL 6 Negative
8 LSIL 6 Negative
9 LSIL 6 Negative
10 LSIL Negative Negative
11 HSIL Negative Negative
12 HSIL 6 Negative
HPV, human papillomavirus; HIV, human immunodeﬁciency virus; LSIL, low-grade
squamous intraepithelial lesion; HSIL, high-grade squamous intraepithelial lesion.
M. Indinnimeo et al. / International Journal of Infectious Diseases 15 (2011) e232–e235e234HIV-negative/HPV-DNA-positive patients with SIL (four cases with
LSIL and one case with HSIL) (Table 3).
In the group of HIV-positive patients, 28 (50%) were both HPV-
DNA- and Pap smear-positive; eight patients (14.3%) were both
HPV-DNA- and Pap smear-negative. Ten patients (17.9%) were Pap
smear-positive and HPV-DNA-negative and 10 patients (17.9%)
were Pap smear-negative and HPV-DNA-positive.
In the group of HIV-negative patients, 17 (34.7%) were both
HPV-DNA- and Pap smear-positive; 18 (36.7%) were both HPV-
DNA- and Pap smear-negative. Eleven patients (22.4%) were Pap
smear-positive and HPV-DNA-negative and three patients (6.1%)
were Pap smear-negative and HPV-DNA-positive (Table 4).
4. Discussion
Several studies have reported the high rate of anal HPV
infection in HIV-positive patients.26 In our studywe found a higher
rate of anal HPV infection by PCR in HIV-positive patients than in
HIV-negative patients with a statistically signiﬁcant difference.Table 4
Pap smear results in HIV-positive and HIV-negative patients
HIV-positive
(number of
patients)
HIV-negative
(number of
patients)
HIV-
positive
(%)
HIV-
negative
(%)
Pap smear-positive 38 28 67.9 57.1
Pap smear-positive/
HPV-DNA-positive
28 17 / /
Pap smear-positive/
HPV-DNA-negative
10 11 / /
Pap smear-negative 18 21 32.1 42.9
Pap smear-negative/
HPV-DNA-positive
10 3 / /
Pap smear-negative /
HPV-DNA-negative
8 18 / /
HIV, human immunodeﬁciency virus; HPV, human papillomavirus.These data could be explained by the immunosuppression, which
plays an important role as indicated by studies showing an
association between anal SIL and low CD4+ T cell counts. In fact a
recent study has suggested that immunosuppression induced by
HIV infection allows the replication of what may otherwise have
been a low level, possibly undetectable, HPV infection, with the
subsequent development of anal cancer.27,28
In contrast, by cytological exam we found an overlapping of
results in the two groups studied. These data may be related to the
type of population enrolled in our study. In fact all of the HIV-
negative group of patients were at high risk of a sexually
transmitted HPV infection for promiscuous and/or MSM behavior.
The numbers having had more than two sexual partners in the last
6 months were similar in both groups, with 27% of HIV-positive
patients vs. 22% of HIV-negative. In addition, all of the HIV-positive
patients were on cART and had recovered their immunological
status, with a mean CD4 T cell count of >500/mm3 and
undetectable HIV-RNA.
Oncogenic strains were found in 39.7% of HPV-DNA-positive
patients; in particular in this group of HPV-DNA-positive patients,
only 10.3% were infected with strains 16 and 18, 8.6% of whom
were HIV-positive and 1.7% HIV-negative, and there was no
signiﬁcant difference between the HIV-positive and HIV-negative
patients. In accordance with Nyitray et al.,27 we think that this low
rate of HPV16 may be a result of certain patient demographic
characteristics. Nyitray et al. found a higher prevalence of HPV16 in
the population of Tampa (USA) than the populations of Sa˜o Paulo
(Brazil) or Cuernavaca (Mexico) and proposed that the distribution
of HPV16 differs by geographical area. In our study all patients
were Caucasian.
SILwere found in12HPV-positivepatients; LSILwere found in10
patients andHSIL in two.Co-infectionwithHIVwasobserved inonly
ﬁve cases. These data show the importance of promiscuous sexual
behavior as a factor that induces HPV co-infection in HIV-positive
patients, in accordance with the study of Mogtomo et al.29 The
distribution of oncogenic strains and the evolution to dysplastic
lesions in the two groups of patients were also not different, andwe
think that this is the result of the recovered immunologic status of
our HIV-positive population. Other authors have also described the
higher incidence of HSIL and cancer in patients with detectable
levels ofHIV-RNA. Sobhani et al., found that patientswithmore than
200HIV-RNA copies/ml in the serumclose to the time of condyloma
relapse were more likely to go on to develop HSIL or cancer. In
addition they showed invasive cancer only in patients with an HIV
load above 1000 HIV-RNA copies/ml in serum.30
In our study HPV-DNA was negative in four of 12 SIL. The
discordance found between the cytological exam and PCR stresses
the importance of the Pap smear in HPV infection screening; in fact
we believe that cytological examination is fundamental to primary
screening. Moreover, in the seven cases of LSIL the isolated strain
was oncogenic in only one case. Thus also in the absence of
oncogenic strains it is necessary to perform a strict follow-up by
cytological exam to avoid the progression of dysplastic lesions. The
concordance between cytological and molecular exam was lower
in the group of HIV-positive patients (64.3%) than in the group of
HIV-negative patients (71.4%). In addition we found that 17.9% of
HIV-positive patients presented a cytological exam positive for
HPV infection but a negative PCR assay; moreover in the group of
HIV-negative patients, 22.4%were positive on cytological exambut
negative on PCR assay.
It ispossible that thehighgradeof inﬂammation that ispresent in
HIV patients and in patients at high risk of sexually transmitted
infectious diseases could have compromised the exact results of the
molecular exam. Currently the PCR assay is extremely sensitive to
contamination from non-template PCR present in the laboratory
environment (from bacteria, viruses, and operator DNA) and this
M. Indinnimeo et al. / International Journal of Infectious Diseases 15 (2011) e232–e235 e235represents a real problem (http://www.pcrstation.com/pcr-limita-
tions/). In additionmost PCR assays are able to detect only the most
frequently found high-risk and low-risk HPV types and they fail to
determine new types of HPV. Thus there are at present several types
of HPV that continue to be underdiagnosed during screening.31
In summary, both HIV-positive and HIV-negative patients at
high risk of developing a sexually transmitted infection should be
submitted to regular screening by cytological andmolecular assays
in order to prevent invasive anal cancer. However, this remains a
controversial topic, and recommendations for anal cytology
screening have not been fully adopted.21 In fact HPV-DNA testing
has become common to complement cervical cytology in the
presence of any one or more HPV viral types, but its use in anal
specimens is contentious. It is not clear if HPV-DNA testing can be
performed as primary screening or as an adjunct to cytology or as a
reﬂex test. To date only Roka et al. have evaluated the use of HPV-
DNA testing as a primary screening method for anal localization.
The results reported by these authors showed that only HPV-
positive patients had anal intraepithelial neoplasia and/or anal
cancer, but there was bias in the study as none of the HPV-DNA-
negative patients underwent anoscopy.32 From our study it is
evident that the molecular exam can be considered as an adjunct
test to complement the cytological exam. In fact we found that
17.9% of HIV-positive patients and 22.4% of HIV-negative patients
were PCR-negative but positive by cytological exam. At the same
time in 33.3% of dysplastic lesions the PCR was negative. However
it is important to underline that this study is limited and based on a
small number of patients.
The Pap smear, for its high sensitivity and low cost, showsmore
advantages compared with the PCR assay.33 The caveat of this
small study concerns the type of HIV population enrolled. In fact
the presence of patients with undetectable levels of HIV viremia
does not allow conclusions to be drawn on the inﬂuence of HIV on
HPV in patients with a compromised immune status.
In conclusion, although the number of samples was limited and
other large-scale studies are needed to assess the signiﬁcance of
the assay results, this study provides a different view on the
cytological exam and the determination of HPV-DNA.
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